Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Change In Payables And Accrued Expense

: $599 Mil (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

Regeneron Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $-139 Mil. It means Regeneron Pharmaceuticals's Accounts Payable & Accrued Expense declined by $139 Mil from Sep. 2023 to Dec. 2023 .

Regeneron Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $599 Mil. It means Regeneron Pharmaceuticals's Accounts Payable & Accrued Expense increased by $599 Mil from Dec. 2022 to Dec. 2023 .

Regeneron Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Regeneron Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

599.00

118.90

866.10

-138.40

598.60

Regeneron Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense																347.60	119.00	39.70	578.60	-138.70

Regeneron Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $599 Mil.

Regeneron Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

REGN:Mexico RGO:Germany RGO:Germany REGN34:Brazil

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Executives

Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Arthur F Ryan	director	CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
George Yancopoulos	director, officer: President and CSO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Huda Y Zoghbi	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Marion Mccourt	officer: SVP Commercial	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael S Brown	director
Christopher R. Fenimore	officer: VP, Controller	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Andrew J Murphy	officer: EVP Research	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Kathryn Guarini	director	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Van Plew Daniel P	officer: EVP & General Mgr Industrial O	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Robert E Landry	officer: SVP Fin, Dep CFO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Neil Stahl	officer: SVP, Preclinical Development	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein	director	DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390